Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double, Blind Placebo-controlled, Randomized Trial to Study Efficacy and Safety of the Viaskin Milk for Treating Milk Induced Eosinophilic Esophagitis in Children

Trial Profile

A Double, Blind Placebo-controlled, Randomized Trial to Study Efficacy and Safety of the Viaskin Milk for Treating Milk Induced Eosinophilic Esophagitis in Children

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Food allergy immunotherapy (Primary)
  • Indications Eosinophilic oesophagitis; Milk hypersensitivity
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SMILEE
  • Most Recent Events

    • 05 Mar 2019 Status changed from active, no longer recruiting to completed.
    • 04 Feb 2019 According to a DBV Technologies media release, abstract related to results from this trial has been published online on the AAAAI meeting website.
    • 04 Feb 2019 According to a DBV Technologies media release, data from this trial will be presented at the 2019 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting; Food Allergy: Advances in Prevention and Treatment in San Francisco, CA, February 22 -25, 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top